Allogene Therapeutics Inc [ALLO] stock prices are up 0.77% to $2.61 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The ALLO shares have gain 13.97% over the last week, with a monthly amount drifted -10.31%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, Piper Sandler started tracking the stock with Overweight rating on May 31, 2024, and set its price target to $11. On January 05, 2024, downgrade downgraded it’s rating to Mkt Perform. Guggenheim downgraded its rating to a Neutral. Citigroup initiated its recommendation with a Buy and recommended $7 as its price target on December 08, 2023.
The stock price of Allogene Therapeutics Inc [ALLO] has been fluctuating between $2.01 and $5.78 over the past year. Currently, Wall Street analysts expect the stock to reach $29 within the next 12 months. Allogene Therapeutics Inc [NASDAQ: ALLO] shares were valued at $2.61 at the most recent close of the market. An investor can expect a potential return of 1011.11% based on the average ALLO price forecast.
Analyzing the ALLO fundamentals
The Allogene Therapeutics Inc [NASDAQ:ALLO] reported sales of 0.09M for trailing twelve months, representing a drop of -100.00%. Gross Profit Margin for this corporation currently stands at -759.84% with Operating Profit Margin at -3148.66%, Pretax Profit Margin comes in at -3237.8%, and Net Profit Margin reading is -3237.8%. To continue investigating profitability, this company’s Return on Assets is posted at -0.43, Equity is -0.54 and Total Capital is -0.44. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.18.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.54 points at the first support level, and at 2.47 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.70, and for the 2nd resistance point, it is at 2.80.
Ratios To Look Out For
It’s worth pointing out that Allogene Therapeutics Inc [NASDAQ:ALLO]’s Current Ratio is 12.25. On the other hand, the Quick Ratio is 12.25, and the Cash Ratio is 4.57. Considering the valuation of this stock, the price to sales ratio is 6064.19, the price to book ratio is 1.06.
Transactions by insiders
Recent insider trading involved Douglas Earl Martin, Officer, that happened on Aug 21 ’24 when 28310.0 shares were purchased. Director, MESSEMER DEBORAH M. completed a deal on Jun 18 ’24 to sell 18641.0 shares. Meanwhile, Director Humer Franz B sold 11200.0 shares on May 30 ’24.
